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Abstract
Somatic mutations have a role in the pathogenesis of a number
of diseases, particularly cancers. Here we present data
supporting a role of mitochondrial somatic mutations in an
autoimmune disease, rheumatoid arthritis (RA). RA is a complex,
multifactorial disease with a number of predisposition traits,
including major histocompatibility complex (MHC) type and early
bacterial infection in the joint. Somatic mutations in
mitochondrial peptides displayed by MHCs may be recognized
as non-self, furthering the destructive immune infiltration of the
RA joint. Because many bacterial proteins have mitochondrial
homologues, the immune system may be primed against these
altered peptides if they mimic bacterial homologues. In addition,
somatic mutations may be influencing cellular function, aiding in
the acquirement of transformed properties of RA synoviocytes.
To test the hypothesis that mutations in mitochondrial DNA
(mtDNA) are associated with RA, we focused on the MT-ND1
gene for mitochondrially encoded NADH dehydrogenase 1
(subunit one of complex I – NADH dehydrogenase) of
synoviocyte mitochondria from RA patients, using tissue from
osteoarthritis (OA) patients for controls. We identified the
mutational burden and amino acid changes in potential epitope
regions in the two patient groups. RA synoviocyte mtDNA had
about twice the number of mutations as the OA group.
Furthermore, some of these changes had resulted in potential
non-self MHC peptide epitopes. These results provide evidence
for a new role for somatic mutations in mtDNA in RA and predict
a role in other diseases.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoim-
mune disease. It is multigenic, possibly triggered by exposure
to viruses or bacteria, and, it is expected, other environmental
stimuli. Consistent with this concept is the strong genetic
association with the HLA-DR allele that contains a QK/RAA
amino acid motif in its third hypervariable region, namely sev-
eral alleles of the HLA-DRβ1 gene. The precise role of HLA-
DR in pathogenesis is unknown, although its role in antigen
presentation is the most obvious [1]. In vitro T-cell proliferation
assays using the susceptible major histocompatibility complex
(MHC) alleles has led to the discovery of a multiplicity of puta-
tive peptide autoantigens including collagen type II, cartilage
link protein, heat shock proteins, and aggrecan [1].
There are nonimmune components to RA. RA synovial fibrob-
lasts have many features of transformed cells – including the
expression of oncogenes – and they have been shown to
invade and destroy cartilage in the absence of T cells [2,3].
The acquisition of these transformed characteristics is thought
to be aided by increased somatic mutations caused by reac-
tive oxygen species (ROS) and reactive nitrogen species
(RNS) produced endogenously within the inflamed joint [4].
Other studies linking ROS and RNS damage to decreased
apoptosis have found ROS-associated damage to p53. The
mutated p53 was a dominant negative, suggesting that p53
mutations help protect pathogenic cells from apoptosis [5-7].
Mitochondrial DNA (mtDNA) damage may complement dam-
age to nuclear regulatory genes and have a causative role in
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the transformation of RA synovial cells. There is limited and
sometimes contradictory evidence available concerning the
ability of mtDNA mutations to lead to increased or decreased
apoptosis [8]. Alterations of mtDNA are now being found in
many tumor types and there is evidence that these mutations
may contribute to the progression of human cancer [9,10].
There is growing evidence that somatic mutations within pro-
tein-coding genes of mtDNA may be recognized by the
immune system: damaged mtDNA results in increased expres-
sion of MHC class I; and both MHC class I and class II can
present mitochondrial peptides [11,12]. Mutated mitochon-
drial peptides in resident cells may, therefore, be aiding in the
recruitment of immunological factors such as cytotoxic T cells
to the RA joint.
Complex I – NADH (reduced nicotinamide-adenine dinucle-
otide) dehydrogenase is exceptionally susceptible to defects
due to mtDNA mutations, because it has the most subunits
encoded by mtDNA. Cells with complex I defects have also
been shown to produce a higher amount of superoxide in vivo
[8,13]. Therefore, defects in complex I may help perpetuate a
vicious cycle of oxidative damage. The murine homologue of
subunit 1 of complex I – NADH dehydrogenase (mtND1) plays
a critical role in self recognition. The maternally transmitted
antigen of rats and mice is the product of a class I molecule
that presents the maternal transplantation factor derived from
the amino terminus of mtND1 [14]. These findings provide evi-
dence that antigenic peptides of human mtND1 may be dis-
played and recognized by the immune system.
To test the hypothesis that mutations in mitochondria play a
role in RA, we examined the MT-ND1 gene of RA synovio-
cytes. As a control we chose synoviocytes from patients with
osteoarthritis (OA). This disease was chosen because it is pri-
marily a noninflammatory syndrome that is not thought to be
directly dependent on the immune system. RA synoviocyte
mtRNA had about twice the number of mutations as the OA
group, revealing a greater mutational burden in RA. Further-
more, some of these changes resulted in changes that were
potential non-self MHC peptide epitopes.
Materials and methods
RNA extraction from tissue and fibroblast lines
The protocol for the use of human tissues was approved by
ethics review committees at the University Health Network and
St Michael's Hospital, Toronto, Canada. Synovial tissues were
obtained from RA and OA patients at the time of arthroplasty.
The patients were not chosen by any criterion other than dis-
ease diagnosis. A portion of each sample was added to Trizol
(Sigma Aldrich, St. Louis, MO, USA) and stored at -80°C until
it was processed according to the manufacturer's instructions.
Synovial fibroblast lines derived from the synovial tissue were
established as previously described [15]. The fourth passage
was used for all RA and OA lines. Cells were maintained in
OptiMEM (Invitrogen Life Technologies, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum and 1% antibi-
otic–antimycotic. They were cultured at 37°C in a humidified
chamber containing 95% air, 5% CO2.
RT-PCR and sequencing
Total RNA extracts from the fibroblasts and tissue of RA and
OA patient samples were amplified using RT-PCR. This was a
two- step protocol using the materials and methods included
with the DuraScript RT-PCR Kit (Sigma Aldrich). In brief, first-
strand cDNA was generated using 50 ng of total RNA, random
nonamers for extension primers, and enhanced avian myelob-
lastosis virus (AMV) reverse transcriptase. Three PCR reac-
tions were then performed using 5 µl first-strand cDNA in each
50 µl PCR. The primer pairs and amplification conditions are
described in Table 1 and have been published previously [16].
Direct sequencing of PCR products does not detect low levels
of heteroplasmy; therefore the PCR fragments were cloned
into a TA vector (using protocols and materials provided in the
TOPO TA Cloning®  Kit for Sequencing with One Shot®
TOP10 Chemically Competent E. coli; Invitrogen, Carlsbad,
CA, USA). Approximately ten colonies from each patient sam-
ple were chosen and sequenced using T3 and T7 primers. To
rule out sequencing errors, only areas of complete identity
(between the T3 and T7 sequence) were aligned with the
mitochondrial Anderson Reference Sequence [17]. Nucle-
otide changes from the reference sequence were recorded
and then entered into the online program MitoAnalyzer
(National Institute of Standards and Technology, Gaithers-
burg, MD, USA; http://www.cstl.nist.gov/biotech/strbase/
mitoanalyzer.html; 2000) which displays the sequence and
any amino acid changes resulting and the position number
affected.
The same amplification and sequencing procedure as above
was followed using PCR primers (Table 1) and conditions pre-
viously published for a nuclear gene, that for dihydrolipamide
dehydrogenase (DLD) [18,19]. Nucleotide changes from the
NCBI (National Center for Biotechnology Information) refer-
ence sequence (gi:5016092) were recorded and correspond-
ing amino acid changes determined.
To control for errors induced by PCR and cloning/transforma-
tion, three plasmids containing cloned fragments were ampli-
fied and sequenced as above (approximately 18,000 bp in
both directions). A methodological error frequency was calcu-
lated (0.00095 errors/bp for total mutational burden and
0.00063 errors/bp for expressed mutational burden) and sub-
tracted from the final mutational burden data before statistical
analyses. Throughout this report, the data presented are cor-
rected for methodological error.Available online http://arthritis-research.com/content/7/4/R844
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Mutational burden comparisons
The mutational burden of OA and RA patients was defined as
the number of mutations identified within that group divided by
the total number of base pairs analyzed. This was then further
separated into two measurements, total mutational burden (all
mutations) and expressed mutational burden (the number of
amino acid changes in the MT-ND1 cDNA from each amplified
region; see Fig. 1). All patients sequenced with the first set of
MT-ND1 primers (1A) had a deletion at nucleotide 3107. The
NCBI reference sequence (gi:17981852) also shows a dele-
tion at this position when compared with the Anderson
sequence (where there is a C) [20]. Since a C at this position
is rarer than the 3107 deletion, the deletion was not included
when calculating mutational burden. All patients sequenced
also had a nucleotide substitution (T to C) at position 1081 in
the DLD gene and, as above, this mutation was also not
included in the calculation of mutational burden. Mutational
burden was compared between RA and OA for each fragment
within the MT-ND1 amplification region and for the amplified
DLD region, using a two-tailed Fisher's exact test.
Known polymorphisms analysis
Reported mtDNA polymorphisms were subtracted from the
total and expressed mutational burden and the values were
reanalyzed, as above. Published polymorphisms were gath-
ered from Mitomap http://www.mitomap.org and a table of the
known polymorphisms found among the patient data is given
in Supplementary Table 1.
Table 1
PCR primers and sequence start position for amplification of MT-ND1 and DLD
Primer name Start position Sequence 5'-3'
mtMT-ND1a
F1A 2995 TTGGATCAGGACATCCCGA
R1A 3645 ACGGCTAGGCTAGAGGTGG
F1B 3536 TTAGCTCTCACCATCGCT
R1B 4239 ATTGTAATGGGTATGGAGACA
F2 4184 TTCCTACCACTCACCCTAG
R2 4869 CATGTGAGAAGAAGCAG
DLDb
DLD – sense 417 ATGATGGAGCAGAAGAGTACTGCA
DLD – antisense 1088 TTTAGTTTGAAATCTGGTATTGAC
aSee Fig. 1 for position of primers. Both forward and reverse primers in addition to the specific nucleotide sequence have a corresponding M13 
tag (M13F, 5'-TGTAAAACGACGGCCAGT- 3' ; M13R, 5'-CAGGAAACAGCTATGACC-3'); start position numbering represents location of 5' 
end corresponding to the Anderson Reference Sequence [17]. bStart position numbering represents location of the 5' end and corresponds to 
the DLD cDNA numbering system published by Pons and colleagues [19]. mt, mitochondrial.
Figure 1
The three amplified and sequenced regions of mtDNA, corresponding to primers given in Table 1 The three amplified and sequenced regions of mtDNA, corresponding to primers given in Table 1. tRNA-Gln is encoded on the negative (or light) 
strand of mtDNA. ND1, NADH-dehydrogenase subunit 1; ND2, NADH dehydrogenase subunit 2.
ND2
+
3536 3645 2995 4869 4184
tRNA-Gln
4239
16S rRNA tRNA-Ile
Amplification region 2 Amplification region 1A
tRNA-Met tRNA-Leu ND1
Amplification region 1BArthritis Research & Therapy    Vol 7 No 4    Da Sylva et al.
R847
Epitope prediction
MHC epitope prediction algorithms were used to search for
possible epitope regions within MT-ND1 for RA susceptible
HLA alleles http://www.jenner.ac.uk/MHCPred/. The algo-
rithm, MHCPred, used published IC50 (median inhibitory con-
centration) values from radioligand competition assays to
develop a predictive algorithm [21]. Given an amino acid
sequence, the program predicts the peptides likely to bind to
the MHC complex (epitopes) and their IC50 values [21]. Pep-
tides with a -logIC50 of more than 6.5 are predicted to be bind-
ers [21].
Results
Mutational burden in OA and RA
OA was used as a nonimmunological-based disease control
for the study. We examined both synovial tissue (patients
OA227, OA315, OA320, and OA324) and synovial fibroblast
lines derived from synovial tissue (patients OA302 and
OA304). Approximately 37 kbp were sequenced from OA tis-
sue and 18 kbp from OA fibroblasts, with 67 (2.1/kbp) muta-
tions and 38 (1.8/kbp) mutations found respectively (Table 2;
Fig. 2).
Table 2
Mitochondrial mutational burden data of OA and RA patient synoviocyte tissue and cultured fibroblasts
Number of mutations Total mutational burden (mutations/kbp) OA vs RAa
Mitochondrial 
mutational burden
Nucleotides 
sequenced
Initial Published 
polymorphisms 
removed
Initial Published 
polymorphisms 
removed
Initial Published 
Polymorphisms 
removed
Total
Fibroblasts
OA 18489 38 20 2.055 1.082
RA 30503 101 65 3.311 2.131 ρ = 0.01 ρ = 6.9 × 10-3
Tissue
OA 37145 67 40 1.804 1.077
RA 17663 60 42 3.397 2.378 ρ = 4 × 10-4 ρ = 5.1 × 10-4
Expressed
Fibroblasts
OA 6956 12 7 1.725 1.006
RA 12394 28 26 2.259 2.098 ρ = 0.5 ρ = 0.10
Tissue
OA 15805 10 10 0.633 0.633
RA 6397 16 14 2.501 2.189 ρ = 6 × 10-4 ρ = 2.7 × 10-3
aTwo-tailed Fisher's exact test. kbp, kilobase pairs; OA, osteoarthritis; RA, rheumatoid arthritis.
Table 3
Nuclear mutational burden data of OA and RA patient tissue and cultured fibroblasts
Patients Nucleotides 
sequenced
Number of total 
mutations
Total mutational 
burden (mutations/
kbp)
Number of amino 
acid changes
Expressed 
mutational burden 
(mutations/kbp)
OA vs RAa
Fibroblasts
OA 10971 36 3.281 24 2.188
RA 7317 15 2.050 10 1.367 ρ = 0.2
Tissue
OA 18287 32 1.750 15 0.820
RA 24522 41 1.672 21 0.856 ρ = 0.2
aTwo-tailed Fisher's exact test. kbp, kilobase pairs; OA, osteoarthritis; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/7/4/R844
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For the RA analyses, we also examined both synovial tissue
(patients RA301C, RA316, RA317, and RA325) and synovial
fibroblast lines (patients RA307 and RA313). Approximately
30 kbp were analyzed from fibroblasts and 18 kbp from tissue,
with 101 (3.3/kbp) mutations and 60 (3.4/kbp) mutations
found respectively (Table 2; Fig. 2). Comparative analyses of
the OA and RA patient data demonstrate significantly more
changes per base pair in RA patients than OA (Table 2,
Fisher's exact P value, ρ < 0.05), whether derived from tissue
or fibroblasts. There may be subgroups within the RA or OA
set as evidenced by the mutation frequencies between RA and
OA patients (Fig. 2). Further studies, with a more detailed
patient history, may help correlate mitochondrial mutations to
disease factors such as age of onset and response to
treatment.
Amino acid (nonsynonymous) changes
The mutations in the gene for MT-ND1 will result in mtND1
protein subunit changes if the mutations created amino acid
changes. mtND1 amino acid changes were found in both OA
and RA samples. In OA, 7 kbp were analyzed from fibroblast
RNA and 16 kbp from tissue RNA. The OA fibroblasts had an
expressed mutational burden of 1.7 amino acid changes per
kilobase pair (12 changes), and tissue 0.63 amino acid
changes per kilobase pair (10 changes) (Table 2; Fig. 2). In
RA, 12.4 kbp of the MT-ND1  gene were analyzed from
fibroblasts and 6.4 kbp from tissue. The RA fibroblasts had an
expressed mutational burden of 2.3 amino acid changes per
kilobase pair (28 changes), and tissue, 2.5 amino acid
changes per kilobase pair (16 changes) (Table 2; Fig. 2).
Thus, there are more amino-acid-changing mutations in RA
patients' MT-ND1 gene in synovial tissue (P < 0.5) (Table 2)
than in OA synovial tissue. Although there are more mutations
in RA than OA cultured fibroblasts, the expressed mutation fre-
quency is not statistically different (2.5 vs 1.7 amino acid
changes per kilobase pair, respectively).
Nuclear DNA mutational burden
A nuclear gene was analyzed to determine whether it, too, had
increased mutations in RA, and thus reveal whether the
changes in mutational frequency were specific to mitochon-
dria. The gene, DLD, was chosen because its product,
dihydrolipoamide dehydrogenase, is a nuclear-encoded mito-
chondrial subunit peptide, constitutively expressed in all cell
types [22]. Mutations were found, as above, in both RA and
OA patients. The total mutational burden was high (approxi-
mately 2 mutations per kilobase pair); however, there were no
significant differences between the RA and OA patient
classes (Table 3).
Epitope prediction and somatic mutations
Several findings suggest that the immune system may aid in
the destruction of cells containing mtDNA mutations [11].
Peptides altered by somatic mutations would be presented by
MHC and may be recognized as non-self. Searches for possi-
ble epitopes in mtND1 led to 76 possible epitopes; of these,
15 were altered by somatic mutations in the RA and OA
patients' mitochondrial samples (data not shown). We chose
to further analyze the 1B amplified fragment of fibroblasts in
more detail because it is totally mRNA-derived (see Fig. 1).
We searched all six predicted HLA-DRβ1*0101 epitopes and
the ten epitopes with highest -logIC50 (pIC50) values for HLA-
DRβ*0401 within the 1B fragment for changes. Changes in
epitope regions were noted, and the new mutated epitope was
submitted to the MHCPred program for prediction of pIC50 val-
ues (Table 4).
Although RA fibroblasts did not have a statistically higher
expressed mutational burden than OA fibroblasts, out of the
16 epitopes investigated, 5 were changed in RA and only 1
was changed in OA. The new (changed) epitopes were ana-
lyzed by the same predictive program and all the new RA
epitopes fell above the pIC50 cutoff value of 6.5M while the
changed OA epitope fell below this cutoff (Table 4).
Figure 2
Mitochondrial mutational burden for OA and RA patients Mitochondrial mutational burden for OA and RA patients. Fibroblast 
data are given in red, tissue data in blue. kbp, kilobase pairsArthritis Research & Therapy    Vol 7 No 4    Da Sylva et al.
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Discussion
These studies revealed that mtDNA somatic mutations were
present in the synovium of RA patients at a higher frequency
than OA controls. We considered the causes of the somatic
mutations (ROS plus selection) as well as the effect these
mutations may be having on the etiology and pathogenesis of
RA.
ROS exposure and survival advantage
Exposure to mutagens, such as ROS, can damage both
nuclear and mitochondrial DNA. The mtDNA is in close physi-
cal proximity to the free-radical-producing process of oxidative
phosphorylation and lacks the protective nucleosome struc-
ture found in nuclear DNA [23]. Additionally, there is limited
ability within mitochondria to repair DNA damage. Together,
these attributes make mtDNA highly prone to damage by ROS
produced by both mitochondria and exogenous sources [24].
ROS introduces mutations. If the mutations were in genes reg-
ulating cell survival, cells that would otherwise stop dividing
and die (from DNA damage) may instead proliferate [4]. Insuf-
ficient apoptosis of resident synoviocytes and inflammatory
cells has been thought to contribute to the persistence of RA
[7]. A higher incidence of lymphoma is also well documented
in RA, and somatic mutations may lead to enhancement of the
aggressive nature of pathogenic cells [25]. For instance, p53
mutations have been found in RA synovial tissues. Their muta-
tions would be predicted to give a growth advantage to the
mutated cells, leading to monoclonal expansion [6]. While
these mutations are most likely a consequence of inflammation
and not the cause of RA, they would be expected to affect dis-
ease progression [1].
The NADPH oxidase system of neutrophils and monocytes
produces ROS upon activation [26]. Accumulation of these
cells within the inflamed joint and the subsequent increase in
ROS may be partially responsible for the increased mtDNA
mutational burden of RA patients. There are two situations in
which nuclear mutations would be expected to occur at
greater frequency in RA patients than in OA controls: first, if
random processes (ROS from the NADPH oxidase) were the
sole cause of the elevated frequency of mtDNA mutations; and
second, if the nuclear mutation is conferring an RA-specific
characteristic (survival advantage) on the synoviocyte. Exam-
ples of the latter instance are the p53 mutations (noted above)
that were not found in peripheral blood from RA patients or
joint tissue from OA patients. It is thought that p53 is randomly
mutated during chronic inflammation by oxygen radicals. Cer-
tain mutations within p53 then confer a survival advantage to
the synoviocytes, giving them 'transformed' characteristics
and participating in the perpetuation of disease [5]. The high
frequency of mutations (approximately 2 mutations per kilo-
base pair) in both patient classes suggests there may be gen-
otoxic stressors in both RA and OA synovia. However, RA
synovial tissue and fibroblasts showed no significant increase
in the randomly chosen nuclear gene over OA controls. This
suggests that the nuclear gene sequenced was not contribut-
ing to the progression of RA and that random mutations
through exogenous ROS cannot, alone, explain the increase in
RA mutational burden found in the mtDNA.
RA is a member of a large class of inflammatory autoimmune
diseases. The presence of exogenous ROS produced by neu-
trophils and monocytes may also be contributing to the pathol-
ogy of other inflammatory autoimmune diseases. Such a
corollary suggests it may be of interest to investigate mtDNA
within other inflammatory autoimmune diseases such as sys-
temic lupus erythematosus.
Altered mitochondrial proteins as non-self
Several findings suggest that the immune system may aid in
the destruction of cells containing mtDNA mutations [11].
Peptides altered by somatic mutations would be presented by
MHC and may be recognized as non-self. Without a similar
Table 4
Predicted epitopes for HLA DRB1*0101 and HLA DRB1*0401 which were changed by nonsynonymous mutations
Patient Amino acid start 
position
Predicted core epitope 
(before mutation)
Predicted -logIC50 (M) New epitope with 
amino acid changea
New predicted -
logIC50 (M)
HLA DRβ*0101
RA313 274 RTAYPRFRY 6.661 RTAHPRFRY 6.896
RA307 99 NLGLLFILA 6.51 SLGLLFILA 6.549
OA302 215 YAAGPFALF 6.681 YAAGPFALS 5.708
HLA DRβ*0401
RA307 259 FVTKTLLLT 7.329 FVAKTLLLT 7.316
RA313 88 PLPMPNPLV 7.093 PLPIPNPLV 6.946
RA307 93 NPLVNLNLG 7.09 NPLVNLSLG 7.148
aBold indicates amino acid changed by mutation; a -logIC50 value above 6.5 is considered to be a binder for prediction purposes. IC50, median 
inhibitory concentration.Available online http://arthritis-research.com/content/7/4/R844
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analysis of mitochondrial RNA from maternal relatives, it is
impossible to say, with certainty, whether all the changes
noted were truly somatic mutations. If somatic mutations were
changing recognition of mitochondrial peptides from self to
non-self, then any inherited changes would be irrelevant.
Although we were unable to obtain samples from maternal rel-
atives of patients, there does exist a database of known mito-
chondrial polymorphisms http://www.mitomap.org. When all
known polymorphisms were subtracted from the data, the sta-
tistical significance of the findings did not change, either for all
mutations or just nonsynonymous changes (Table 2).
There are no known data that address the antigenic nature of
mitochondrial proteins in RA. However, there is evidence for
the involvement of mitochondrial antibodies in another form of
arthritis, polymylagia rheumatica. Temporal or giant-cell arteri-
tis is an inflammatory large-vessel disease associated in many
patients with polymyalgia rheumatica, and while the etiology of
giant-cell arteritis/polymyalgia rheumatica is unclear, there is
evidence to support the role of immune mechanisms in its
pathogenesis, including the discovery of five autoantigens in
patients with the disease [27,28]. Moreover, one of these
autoantigens is a mtDNA-encoded subunit of complex IV
(cytochrome c oxidase subunit II [28]), implicating mtDNA-
derived proteins in autoimmune disease.
Our studies predicted numerous regions within mtND1 that
may be possible epitopes for HLA-DRβ1*0101 and HLA-
DRβ1*0401 (RA-associated HLAs). Five of these possible
epitopes were mutated in RA patients and one was mutated in
OA. The new (mutated) peptides were analyzed and found to
still be possible epitopes for the RA patients, but the OA
patient's mutation caused the mutated epitope to fall below
the cutoff value for HLA binding (Table 4). Therefore, peptides
from mitochondria have the potential to be presented by MHC
II, and somatic mutations may alter the peptide such that it is
recognized as non-self. As a result, recognition by the immune
system of mitochondrial peptides may be aiding in the recruit-
ment of T cells and inflammatory factors, helping to sustain the
synovial inflammation characteristic of RA.
Conclusion
This study demonstrates, for the first time, that mtDNA somatic
mutations are present in high frequency in the synovia of RA
patients. There are two possible effects of somatic mitochon-
drial mutations on RA. These somatic mutations may be influ-
encing cellular function, aiding in the acquisition of
transformed properties of RA synoviocytes. Second, somatic
mutations in peptides displayed by MHC may also be causing
an immune reaction, which would further the destructive
immune infiltration of the RA joint. The immune system may be
primed against these altered peptides because of mimicry with
bacterial homologues. Either of these processes would aid in
progression of the disease, and earlier immune recognition of
mitochondrial peptides may also play a causative role in RA.
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